Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes

Open access
Roufosse, Florence E., Kahn, Jean-Emmanuel, Gleich, Gerald J., Schwartz, Lawrence B., Singh, Anish D., Rosenwasser, Lanny J., Denburg, Judah A., Ring, Johannes, Rothenberg, Marc E., Sheikh, Javed, Haig, Ann E., Mallett, Stephen A., Templeton, Deborah N., Ortega, Hector G., Klion, Amy D. · 2013 · Journal of Allergy and Clinical Immunology

Abstract

Background Hypereosinophilic syndromes (HES) are chronic disorders that require long-term therapy to suppress eosinophilia and clinical manifestations. Corticosteroids are usually effective, yet many patients become corticosteroid-refractory or develop corticosteroid toxicity. Mepolizumab, a humanised monoclonal anti-interleukin-5 antibody, demonstrated corticosteroid-sparing effects in a double-blind, placebo-controlled study of FIP1L1/PDGFRA-negative, corticosteroid-responsive subjects with HES. Objective To evaluate long-term safety and efficacy of mepolizumab (750 mg) in HES. Methods MHE100901 is an open-label extension study. The primary endpoint was the frequency of adverse events (AEs). Optimal dosing frequency, corticosteroid-sparing effect of mepolizumab, and development of anti-mepolizumab antibodies were also explored. Results Seventy-eight subjects received 1–66 mepolizumab infusions each (including mepolizumab infusions received in the placebo-controlled trial). Mean exposure was 251 weeks (range 4–302). The most common dosing interval was 9–12 weeks. The incidence of AEs was 932 events per 100 subject-years in the first year, declining to 461 events per 100 subject-years after 48 months. Serious AEs, including one death, were reported by the investigator as possibly due to mepolizumab in three subjects. The median daily prednisone dose decreased from 20.0 to 0 mg in the first 24 weeks. The median average daily dose for all subjects over the course of the study was 1.8 mg. Sixty-two percent of subjects were prednisone-free without other HES medications for ≥12 consecutive weeks. No neutralizing antibodies were detected. Twenty-four subjects withdrew prior to study completion for death (n=4), lack of efficacy (n=6), or other reasons. Conclusion Mepolizumab was well tolerated and effective as a long-term corticosteroid-sparing agent in PDGFRA-negative HES.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2012.07.055

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 178

Metadata

Authors
Roufosse, F. E., Kahn, J.-E., Gleich, G. J., Schwartz, L. B., Singh, A. D., Rosenwasser, L. J., Denburg, J. A., Ring, J., Rothenberg, M. E., Sheikh, J., Haig, A. E., Mallett, S. A., Templeton, D. N., Ortega, H. G., & Klion, A. D.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2013-02
Volume
131
Issue
2
Pages
461-467.e5
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2061276567
Cited by
178
References
1
FWCI
8.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. https://app.cochat.ai/papers/10.1016/j.jaci.2012.07.055
The paper
Roufosse, F. E., Kahn, J.-E., Gleich, G. J., Schwartz, L. B., Singh, A. D., Rosenwasser, L. J., Denburg, J. A., Ring, J., Rothenberg, M. E., Sheikh, J., Haig, A. E., Mallett, S. A., Templeton, D. N., Ortega, H. G., & Klion, A. D. (2013). Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2012.07.055

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.